Koers Celyad Oncology SA OTC Markets
Aandelen
CYADY
US1512052002
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | 102K 110K | Marktkapitalisatie | 16,16 mln. 17,39 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -40 mln. -43,05 mln. | Nettowinst (verlies) 2023 | -8 mln. -8,61 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 12,19 mln. 13,12 mln. | Nettoliquiditeiten 2023 | 5,95 mln. 6,4 mln. | EV/omzet 2023 | 100 x |
K/w-verhouding 2022 |
-0,28
x | K/w-verhouding 2023 |
-1,19
x | Werknemers | 18 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 92,37% |
Recentste transcriptie over Celyad Oncology SA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 24-07-07 |
David Georges
DFI | Director of Finance/CFO | - | 01-01-19 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 24-07-07 |
Hilde Windels
CHM | Chairman | 59 | 07-05-18 |
Serge Goblet
BRD | Director/Board Member | - | 01-01-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |